OBMP - OncBioMune Pharmaceuticals, Inc.

Discussion in 'Penny Stocks' started by Jim BooDog, Jun 15, 2017.

  1. Jim BooDog

    Jim BooDog Active Member

    Joined:
    Apr 7, 2016
    Messages:
    150
    Likes Received:
    40
    OncBioMune Pharmaceuticals, Inc.

    http://oncbiomune.com/

    http://oncbiomune.com/stock-information/

    60,207,846 shares as of May 22, 2017.

    500,000,000 shares authorized

    Filings
    https://www.sec.gov/cgi-bin/browse-edgar?company=oncbiomune&owner=exclude&action=getcompany


    Their profile needs to be updated big time. I've spoken with the company about this today actually.

    OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary vaccine technology that is designed to stimulate the immune system to selectively attack cancer cells without harm to the patient. The vaccine technology has been proven safe through use in more than 300 patients without a single serious adverse event. Our lead product, ProscaVax™ for prostate cancer, is near conclusion of a Phase 1 trial funded by the Department of Defense Navy Cancer Vaccine Program. Based upon data showing ProscaVax is non-toxic and can lower PSA levels, we are moving ProscaVax into a Phase 2 trial for prostate cancer patients in the “Active Surveillance” category, an early stage of disease for which there are currently no treatments without significant morbidities. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs, including paclitaxel (Abraxane). OncBioMune is headquartered in Baton Rouge, LA.
     
  2. Jim BooDog

    Jim BooDog Active Member

    Joined:
    Apr 7, 2016
    Messages:
    150
    Likes Received:
    40
    OncBiomune's ProscaVax phase 2 trial investigators Beth Israel Deaconess Medical Center of Harvard Medical School...


    Glenn J. Bubley, MD, Director of Genitourinary Oncology
    Dr. Glenn Bubley is a renowned expert in genitourinary (GU) medical oncology with a primary focus on prostate cancer. As director of the multidisciplinary genitourinary cancer program involving medical, surgical and radiation oncologists as well as pathologists and basic scientists, he heads numerous clinical/translational trials. He is Co-Principal Investigator for the prestigious Prostate SPORE (Specialized Programs of Research Excellence) at the Dana Farber/Harvard Cancer Center. The research is a pilot of the development of an anti-prostate cancer agent specifically targeted to prostate cancer cells. He oversees the Hershey Family Prostate Cancer Tissue Bank and Data base at BIDMC, which has more than 1,000 specimens from prostate cancer patients over the past 13 years and directs interventional research for GU oncology as well, overseeing approximately 13 open trials for patients with prostate or bladder cancer. Dr. Bubley has authored numerous scientific, research and translation papers and articles in his area of expertise, prostate cancer. He serves as at BIDMC and is Associate Professor of Medicine at Harvard Medical School.


    Rupal Bhatt, MD, PhD, MMS
    Dr. Rupal Bhatt is Assistant Professor of Medicine at Harvard Medical School, an attending physician in the GU Oncology Program and researcher Dr. Bhatt currently cares for patients with prostate, bladder and testis cancer and has participated in clinical trials in these fields. Dr. Bhatt focuses her research on Renal Cell Carcinoma and Prostate Cancer with a special interest in the Mechanisms of Resistance to Antiangiogenic Therapy. For this work, she was awarded Young Investigator Awards from AACR and ASCO and was also was awarded the ASCO Career Development Award. Currently Dr. Bhatt is in the second year of her five-year Mentored Clinical Scientist Development Award from the National Cancer Institute designed to train clinicians committed to a career in laboratory or field-based research or to translational research with a laboratory focus.

    She completed her medical training and graduate training at Cornell University Medical College and The Rockefeller University, where she received her MD/PhD degrees. She trained at BIDMC as an intern and resident and began her research at BIDMC as well as joining the Hematology and Oncology Fellowship program and was recruited to join the medical staff as an attending physician in 2006. In addition to her clinical work and research Dr. Bhatt received her Masters of Medical Science during her participation in the Clinical Investigator Training Program in 2008.

    http://www.bidmc.org/Centers-and-Departments/Departments/Cancer-Center/Genitourinary-Oncology-Program/Meet-our-team.aspx


    Thank you gmwestrup!!!

    David Johnson Einstein, MD
    Oncology Boston, MA
    Genitourinary Oncology, Hematologic Oncology, Hospice & Palliative Fellow, BIDMC

    Office Address
    800 Washington St
    Boston, MA 02111Phone:(617) 667-2100

    Title Clinical Fellow in Medicine (EXT)
    Institution Beth Israel Deaconess Medical Center
    Department Medicine
    Address Beth Israel Deaconess Medical Center
    Department of Medicine - Rabb 430
    330 Brookline Ave
    Boston MA 02215
    Phone 617/667-9278
    Fax 617/975-5009
    Email

    Education & Training
    Tufts Medical CenterTufts Medical Center

    Residency
    Tufts University School of MedicineTufts University School of Medicine
    Medical School

    Other Training Certifications & Licensure
    MA State Medical LicenseMA State Medical License 2011 - 2017
    American Board of Internal Medicine
    Internal Medicine

    Awards, Honors, & Recognition
    Merit Award in Palliative Care
    Conquer Cancer Foundation of ASCO, 2014
    Excellence in Teaching Award
    Tufts University School of Medicine, 2014
    Notable Teaching Citation
    Tufts Medical Center Department of Medicine, 2013

    Publications & Presentations
    PubMed Improving End-of-Life Care: Palliative Care Embedded in an Oncology Clinic Specializing in Targeted and Immune-Based Therapies.
    Einstein, D. J.,DeSanto-Madeya, S.,Gregas, M.,Lynch, J.,McDermott, D. F.,Buss, M. K.; J Oncol Pract. 2017 Jun 01.
    Against "Healthy Paternalism" at the End of Life-Reply.
    Mathew P, Einstein DJ, Ladin K; JAMA Oncol. 2016-06-01.
    The Ethical Imperative of Healthy Paternalism in Advance Directive Discussions at the End of Life.
    Einstein, D. J.,Ladin, K.,Mathew, P.; JAMA Oncol. 2016 Feb 26.

    Journal Articles
    The ethical imperative of healthy paternalism in advance-directive discussions at the end of life Einstein DJ, Ladin K, and Mathew P, JAMA Oncol, 1/25/2016
    Dying for advice: code-status discussions between resident physicians patients with advanced cancer-a national survey Einstein DJ, Einstein KL, and Mathew P, J Palliat Med, 1/1/2015
    A problematic palsy: an exercise in clinical reasoning Einstein DJ, Trowbridge RL, and Rencic J, J Gen Int Med, 1/1/2015

    Abstracts/Posters
    "Expanded Prostate Cancer Index Composite-26 Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life after Treatment for Lo... Einstein DJ, American Urological Association Annual Meeting, San Diego, CA, 1/1/2016
    "Dying for advice: code-status discussions between resident physicians patients with advanced cancer-a national survey." Einstein DJ, ASCO Palliative Care in Oncology Symposium, Boston, MA, 1/1/2014
    Lectures
    "'Who Am I to Say?' The Role of Residents in Advance Care Planning." Boston, MA - 1/1/2016

    Press Mentions
    Peuxvn4ujpboexs1qudvDigital Journal
    June 2017



    BATON ROUGE, LA—(June 01, 2017) – OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (“OncBioMune” or the “Company”), a clinical stage biopharmaceutical company engaged in the development of targeted cancer therapies and a proprietary vaccine technology, is pleased to announce that the protocol for the Company’s upcoming Phase 2 clinical trial of ProscaVax as a novel therapeutic cancer vaccine for early stage prostate cancer has been submitted to the U.S. Food and Drug Administration (FDA) for review. In the trial, ProscaVax will be evaluated for safety, tolerability and efficacy as a treatment for patients at disease presentation who, in collaboration with their oncologist, chose to forego standard approved therapies in favor of careful monitoring for disease progression, a process known more commonly as “active surveillance.”

    ProscaVax is an immunotherapeutic cancer vaccine consisting of a combination of the tumor-associated antigen PSA (prostate specific antigen) with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF).

    There are currently no FDA-approved treatments for patients in active surveillance. Today’s approved therapies for early-stage prostate cancer include surgery to remove the prostate and some surrounding tissue (radical prostatectomy), radiation and brachytherapy, all of which are well documented to have unpleasant side effects, including impotence and urinary incontinence.

    As submitted, the Phase 2 clinical protocol will randomly enroll 120 early stage prostate cancer patients with 40 patients on standard active surveillance and 80 patients receiving ProscaVax. The patients’ PSAs and yearly biopsies will be monitored for disease progression. The follow-up of the patients will be for two years. The investigators are Dr. Rupal Bhatt, Dr. Glenn Bubley and Dr. David Einstein at Beth Israel Deaconess Medical Center of Harvard Medical School. Early clinical research of ProscaVax, including a Phase 1 Clinical Trial that recently completed enrollment in PSA progressing prostate cancer in hormone-naïve and hormone-independent patients, has shown ProscaVax to be well tolerated with a strong safety profile. Data from late-stage patients further shows signs of efficacy with respect to an increased immune response and slowing tumor progression.

    http://oncbiomune.com/2017/06/01/protocol-submitted-to-fda-for-phase-2-clinical-trial-of-proscavax-as-immunotherapy-for-early-stage-prostate-cancer/

    We should hear something in early July on this imo.
     
  3. Jim BooDog

    Jim BooDog Active Member

    Joined:
    Apr 7, 2016
    Messages:
    150
    Likes Received:
    40
    http://oncbiomune.com/ $OBMP briefing

    Market Value $12,942,628 a/o Jun 21, 2017
    Authorized Shares 500,000,000 a/o May 31, 2017
    Outstanding Shares 132,473,162 a/o May 31, 2017
    -Restricted 116,550,685 a/o May 31, 2017
    -Unrestricted 15,922,477 a/o May 31, 2017
    Held at DTC 15,776,987 a/o May 31, 2017

    BATON ROUGE, LA--(Marketwired - June 01, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of targeted cancer therapies and a proprietary vaccine technology, is pleased to announce that the protocol for the Company's upcoming Phase 2 clinical trial of ProscaVax as a novel therapeutic cancer vaccine for early stage prostate cancer has been submitted to the U.S. Food and Drug Administration (FDA) for review. In the trial, ProscaVax will be evaluated for safety, tolerability and efficacy as a treatment for patients at disease presentation who, in collaboration with their oncologist, chose to forego standard approved therapies in favor of careful monitoring for disease progression, a process known more commonly as "active surveillance."
    ProscaVax is an immunotherapeutic cancer vaccine consisting of a combination of the tumor-associated antigen PSA (prostate specific antigen) with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF).
    There are currently no FDA-approved treatments for patients in active surveillance. Today's approved therapies for early-stage prostate cancer include surgery to remove the prostate and some surrounding tissue (radical prostatectomy), radiation and brachytherapy, all of which are well documented to have unpleasant side effects, including impotence and urinary incontinence.



    MEXICO CITY, MEXICO--(Marketwired - June 19, 2017) - OncBioMune México, S.A. De C.V., (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies and owner of vaccine technology and commercialization of a portfolio of products internationally announced the completion of the acquisition of the sanitary registration and intellectual property rights of Norepinefrine (Norepinephrine) for the Mexican market from Teva Pharmaceuticals Mexico, S.A. de C.V. (Teva), the Mexican subsidiary of Teva Pharmaceuticals, Ltd., a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 100 markets every day.



    BATON ROUGE, LA--(Marketwired - May 23, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce that its contract manufacturing organization (CMO) has begun formulation work on tretinoin, also known as all-trans retinoic acid (ATRA), at its state-of-the-art, cGMP-compliant facility in Colombia. Tretinoin is an oral drug for the treatment of Acute Promyelocytic Leukemia (APL). OncBioMune has acquired commercialization rights for tretinoin throughout Mexico, Central America and Latin America from the leading South American CMO. Formulation work will be followed by stability studies, with expectations for commercialization of tretinoin under the OncBioMune brand across Mexico, Central America and Latin America in 2018.



    OncBioMune Provides Corporate Update, Nearly 50 Drug Candidates in Pipeline or Being Negotiated
    BATON ROUGE, LA--(Marketwired - May 09, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of targeted cancer therapies and a proprietary vaccine technology, is pleased to provide a corporate update on corporate and clinical developments thus far in the first half of 2017.

    When OncBioMune chose to enter the public markets in late in September 2015, management was charged with two primary directives to build shareholder value. One was to advance ProscaVax through a phase 1 study into mid-stage trials with the ultimate goal of late-stage research and commercialization as the world's first therapeutic prostate cancer vaccine. The second was to employ an aggressive acquisition strategy for a variety of purposes, including generating revenue to fund R&D activity and additional acquisitions. Approximately one and a half year later, the Company continues to effectively execute on this business model. Since the start of 2017, OncBioMune has announced:

    Completing the acquisition of Vitel Laboratorios S.A. de C.V. ("Vitel"), establishing OncBioMune Mexico S.A. de C.V. as a wholly-owned Mexico City-based subsidiary of OncBioMune as it integrates Vitel's operations into a component of the Company. The acquisition transitioned OncBioMune into a revenue-generating company with two recently commercialized drugs and a portfolio of others either already licensed or in negotiations for licensing or acquisition.
    Sales in Mexico from September 16, 2016 to April 17, 2017 for Bekunis® for constipation and Cirkused® for stress were approximately US$350,000, exceeding projections for US$155,000 initially forecast for the first seven months at product launch during the third quarter of 2016. The Company anticipates that sales efforts will continue to accelerate and anticipates combined sales in the range of US$750,000 to US$850,000 for the products in 2017.
    Completing enrollment in the Phase 1 study of ProscaVax evaluating the novel therapeutic cancer vaccine in the treatment of prostate specific antigen (PSA) recurrent prostate cancer in hormone-naïve and hormone-independent patients.
    Presenting an abstract illustrating research on ProscaVax at the American Association for Cancer Research (AACR) Annual Meeting 2017 in Washington, D.C. Data to date from the trial supports the strong safety profile of ProscaVax while also providing evidence of efficacy with respect to slowing tumor growth and increasing an immune response.
    Receiving authorization to perform the protocol proposed for the Phase 2/3 clinical trial of ProscaVax from the Department of Urology of the High Specialty Hospital IMSS Siglo XXI ("HSH IMSS") in Mexico. This approval followed that of Department of Oncology, meaning that the two departments both offered their support to the Phase 2/3 study of ProscaVax set to commence in Mexico for the treatment of in PSA recurrent prostate cancer in hormone-naïve and hormone-independent patients.
    Acquiring tretinoin, also known as all-trans retinoic acid (ATRA), an oral drug for the treatment of Acute Promyelocytic Leukemia (APL) for commercialization throughout Mexico, Central America and Latin America. This was originally announced as a license agreement.
    Submitting to COFEPRIS, Mexico's equivalent of the U.S. Food and Drug Administration, requisite documentation seeking marketing authorization of the Anti-D immunoglobulin product marketed as KamRho® and licensed by OncBioMune for the Mexican market. Anti-D immunoglobulin is listed on the World Health Organization's List of Essential Medicines.
    Partnering with AqVida GmbH, a Germany-based FDF manufacturer specializing in the development, registration, manufacturing and distribution of generic pharmaceutical products, for the purpose commercializing AqVida's portfolio of products in Mexico. AqVida and OncBioMune are further negotiating AqVida's interest to spearhead clinical trials and development of ProscaVax for the European markets.
    The signing of a non-binding term sheet to develop mid-stage GPX-150 compound (5-imino-13-deoxydoxorubicin) in the Mexico, Central and Latin America markets for several hard-to-treat diseases and conditions. The partner has successfully completed a Phase 2 trial in the United States that met safety goals and demonstrated a therapeutic benefit in adult patients with metastatic and nonresectable soft tissue sarcoma.
    The signing of a non-binding term sheet with the world's biggest generic drug manufacturer regarding licensing Norepinefrine as indicated for the treatment of low blood pressure and heart failure for commercialization in the Mexican and other Central and Latin American countries.
    The signing of a non-binding term sheet with for the purpose of development and commercialization of telatinib in 34 countries across Mexico, Central and Latin America. More specifically, the term sheet identified the clinical development of the potent oral VEGFR2/3 inhibitor telatinib for the treatment of gastric cancer.
    The decision, based upon the guidance of Glenn J. Bubley, M.D., Associate Professor, Medicine Harvard Medical School and Director, Genitourinary Medical Oncology, Beth Israel Deaconess Medical Center and the Principal Investigator for the planned Phase 2 study of ProscaVax for early-stage prostate cancer patients in the "active surveillance" category to be hosted at a major Northeast U.S. university cancer center, to submit the study to the Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute. CTEP coordinates the clinical therapeutics development program of the Division of Cancer Treatment and Diagnosis (DCTD) by reviewing clinical trials and evaluating their merits for collaboration and funding.
    "We're very proud of all that we have accomplished in a very short period of time so far in 2017," commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. "We're are hitting on all cylinders, but really feel like we are only beginning to hit our stride. As final preparations transpire to commence the two trials of ProscaVax, we're extremely active in discussions to acquire, license or partner for drugs in Mexico and neighboring markets. At this moment, there are a total of 48 drugs/drug candidates that are already under our control for specific markets or are the subject of negotiations. There is a lot of work in front of us to finalize agreements and bring products to market, but all is going according to design with revenue coming in and deals in the works that can bolster revenue many fold in the coming years as ProscaVax moves down the clinical path. We're more confident than ever that we'll look back on 2017 as a transformational year for our company by maintaining our course and continuing to successfully meet milestones."
     
  4. Edson wag

    Edson wag Member

    Joined:
    Apr 6, 2016
    Messages:
    105
    Likes Received:
    9
  5. Edson wag

    Edson wag Member

    Joined:
    Apr 6, 2016
    Messages:
    105
    Likes Received:
    9

Share This Page